Ever in search of novel therapeutic targets for cancer, Dr. Raymond Mattingly’s work in cellular and molecular pharmacology is never done. His studies are providing evidence that tumorigenesis may be triggered by inappropriate expression and control of the Ras protein and its exchange factor, Ras-GRF.

In honor of his work, Dr. Mattingly, assistant professor of pharmacology, has received a Faculty Development Award in Basic Pharmacology and Toxicology from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. This award, given to only two researchers annually, provides two years of funding assistance for innovative scientific programs.

Robert Ingram, PhRMA chairman, said, “Our tradition of providing financial support to young scientists continues as one of our top priorities. Our support will help them jump-start careers in disciplines important to research-intensive industries. Our goal is to encourage a focus on cutting-edge fields that promote innovation.”

Dr. Mattingly has shown that the exchange factor activity of Ras-GRF is increased by stimulation of G protein-coupled receptors that act to increase the serine phosphorylation state of Ras-GRF. This research project has three aims. His first goal is to map the regulatory phosphorylation sites of Ras-GRF. Second, he will characterize those sites. Finally, he hopes to understand the multiple regulatory factors involved in the control of Ras-GRF.

“These studies will greatly increase our knowledge of the control mechanisms for Ras and may identify new pharmacological approaches to human cancer,” said Dr. Mattingly.

This work is supported in part by the National Institutes of Health and the American Cancer Society.